ICU Medical (NASDAQ:ICUI) Given New $209.00 Price Target at KeyCorp

ICU Medical (NASDAQ:ICUI) had its target price hoisted by KeyCorp from $198.00 to $209.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Other research analysts have also recently issued reports about the company. StockNews.com cut ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday. Raymond James increased their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group started coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Stock Down 2.7 %

Shares of ICUI traded down $4.75 during mid-day trading on Wednesday, hitting $170.06. 4,202 shares of the company’s stock were exchanged, compared to its average volume of 273,665. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -38.25 and a beta of 0.66. The stock’s 50-day moving average is $176.11 and its 200-day moving average is $141.98. ICU Medical has a fifty-two week low of $82.82 and a fifty-two week high of $196.26.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.04% and a negative net margin of 4.74%. The business had revenue of $580.07 million for the quarter, compared to analyst estimates of $574.77 million. On average, sell-side analysts anticipate that ICU Medical will post 3.81 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,096,771.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,502 shares of company stock valued at $8,445,976. 6.70% of the stock is owned by corporate insiders.

Institutional Trading of ICU Medical

Large investors have recently added to or reduced their stakes in the stock. Scout Investments Inc. raised its stake in shares of ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after purchasing an additional 7,272 shares during the period. SG Americas Securities LLC grew its stake in shares of ICU Medical by 441.7% during the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after acquiring an additional 4,744 shares in the last quarter. Sei Investments Co. increased its position in shares of ICU Medical by 52.1% during the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock worth $3,068,000 after acquiring an additional 9,793 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after purchasing an additional 145,485 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in ICU Medical by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.